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SUMMARY – New data gathered from large clinical trials indicate that nonobstructive coronary 
artery disease (non-CAD) is a clinical entity that should not be ignored. It is estimated that 50% of 
female population undergoing coronarography are diagnosed with non-CAD. Th ere is also an increase 
in the prevalence of non-CAD in both genders, which is probably due to gradual expanding of clinical 
indications for angiography in patients with angina. Furthermore, considering the increased mortality 
risk established recently, a prognosis of non-CAD is not benign as previously thought. However, the 
concept and defi nition of non-CAD remains elusive causing diffi  culties in diagnosis and treatment. 
One of the major shortcomings is the exclusion-based diagnosis of non-CAD. Furthermore, treat-
ment of non-CAD still presents a great challenge and optimal therapy is yet to be determined. Th ere 
are two major hypotheses explaining the pathophysiological mechanisms of non-CAD, i.e. ischemic 
hypothesis based on abnormal microvascular dysfunction and non-ischemic one based on altered pain 
perception. Th is review encompasses a broader spectrum of pathophysiological mechanisms of 
 non-CAD, and proposes a new way of classifi cation based on the major disorder involved: type I 
(ischemic mechanisms) and type II (non-ischemic mechanisms), depending on which mechanism 
predominates. Hopefully, this would provide new insights in the understanding of this disorder, thus 
leading to accurate and early diagnosis and successful treatment, especially considering the increased 
mortality risk in these patients.
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Introduction
Th e concept of coronary syndrome X (CSX) was 
introduced in clinical practice in 1973 by Kemp et al. 
to describe patients with angina during physical exer-
cise and normal coronarography1-3. Over time, this 
term has encompassed a broader spectrum of patients 
including those with angina regardless of the cause 
and absence of signifi cant changes on coronary ves-
sels2. Patients with other cardiac pathology such as 
cardiomyopathies, left ventricular hypertrophy or sig-
nifi cant valvular disease are usually, although not al-
ways, excluded from this defi nition4. Many authors 
recommend associating this syndrome with angina 
and microvascular dysfunction5. On the other hand, 
some authors suggest exclusion of certain diseases, 
such as hypertension or diabetes, which can lead to 
microvascular dysfunction6.
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Classic defi nition of CSX is: angina during physi-
cal exertion, signifi cant changes of ST segment during 
exercise test, and angiographically smooth coronary 
arteries in the absence of other cardiac or systemic dis-
eases (e.g., hypertension and diabetes), which can lead 
to vascular dysfunction6. Th is defi nition is presently 
inappropriate for research and clinical purpose, the 
main objection being the impossibility of including all 
patients with microvascular dysfunction5. Hence, new, 
more appropriate defi nitions have recently been intro-
duced by scientifi c community.
Lanza has proposed that CSX consists of chest 
pain predominantly during physical exertion, estab-
lished ischemia or diminished coronary reserve, using 
noninvasive provocation tests, normal (or almost nor-
mal) coronary arteries at angiography with stenosis 
less than <20%, and exclusion of other specifi c diseases 
such as Prinzmetal’s angina, cardiomyopathies and 
valvular heart disease5. Accordingly, the CSX now in-
cludes not only conditions with diminished coronary 
reserve that can be established with modern diagnostic 
procedures of ergometry, stress induced myocardial 
scintigraphy, pharmacological stress tests or ECG 
Holter monitor test, but also other diseases such as hy-
pertension or diabetes, which are common causes of 
microvascular dysfunction7.
Owing to the new understandings, Cannon and 
Epstein introduced a new concept of microvascular 
angina in 19858. Th is concept defi nes CSX as chest 
pain with normal coronary angiography associated 
with enhanced sensitivity of microcirculation to vaso-
constrictive infl uences or abnormal vasodilatory re-
sponse due to endothelial dysfunction. Th e level of 
endothelin (vasoconstrictor) in plasma of these pa-
tients is signifi cantly increased9. Th is was an attempt to 
unite pathophysiology of the clinical condition, accen-
tuate signifi cant role of endothelial dysfunction, and 
achieve a more homogeneous group of patients. How-
ever, this approach is not fully satisfying since it be-
comes more obvious that endothelial dysfunction is 
only part of the pathophysiological cascade.
In 2011, Kothawade et al. suggested a new term of 
microvascular coronary dysfunction (MCD)10. Th e 
CSX is defi ned as diminished coronary reserve and/or 
coronary endothelial dysfunction, and is clinically pre-
sented with a triad of symptoms: persistent chest pain, 
nonobstructive coronary disease (coronary artery ste-
nosis <50% on coronarography), and ischemia estab-
lished with noninvasive methods10. Th e gold standard 
for MCD diagnosis is invasive coronary reactivity test-
ing (CRT)10.
Regardless of defi nition and terminology, it is nec-
essary to emphasize that obstructive coronary disease 
(CAD) indicates stenosis of coronary vessel ≥50% on 
coronarography, while nonobstructive coronary disease 
(non-CAD) indicates stenosis of coronary artery 
<50%11. Th at criterion is common to all defi nitions and 
understandings of this complex clinical syndrome.
However, there are still some diff erences in under-
standing non-CAD that cause discrepancies in results 
and observations. Th erefore, new defi nitions should be 
considered to enable unique and accurate defi ning of 
this clinical entity with all its diversities.
Nonobstructive Coronary Artery Disease 
– Pathophysiological Mechanisms
Th ere are two major hypotheses explaining the 
pathophysiological mechanisms of non-CAD, i.e. 
ischemic and non-ischemic hypotheses12. Ischemic 
theory is based on abnormal microvascular dysfunc-
tion, whereas non-ischemic theory is grounded on al-
tered pain perception12-16.
Ischemic hypothesis
Since the time when CSX was recognized as a spe-
cifi c clinical entity, it was assumed that chest pain was 
caused by dysfunction of small coronary arteries (<500 
μm), not seen during coronarography, hence naming 
the whole syndrome microvascular angina8. Myocar-
dial ischemia in these patients can be established by 
ST segment changes at rest or exertion and by perfu-
sion redistribution on scintigraphy13. Moreover, there 
is some metabolic evidence for ischemia during exer-
cise, e.g., increased lactate production, decreased oxy-
gen saturation in coronary sinus, decreased pH and 
increased phosphate consumption on nuclear mag-
netic resonance (NMR), which can be confi rmed in 
20% of patients15.
However, not all studies managed to demonstrate 
the presence of ischemia since disturbance of regional 
contractility was not confi rmed by echocardiography16. 
In 1991, Maseri et al.14 tried to explain this contradic-
tory observation with the following hypothesis. Mi-
crovascular dysfunction encompasses small prearterio-
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lar vessels (100-500 μm), while their inadequate vaso-
dilative response during exercise or pharmacological 
stress tests leads to localized ischemia surrounded by 
areas with functioning arteriolar vessels. Th is induces 
compensatory response by increasing contractility, 
thus preventing diagnosis of regional or global con-
tractility disturbance by echocardiography.
Coronary fl ow is regulated by endothelial depen-
dent and non-endothelial dependent factors, which 
regulate macro- and microvascular blood vessel tone. 
Endothelial dependent factors regulate coronary re-
serve modulating vasomotor tone by releasing vasoac-
tive factors. Th e most important vasodilator is nitric 
oxide (NO), a factor released by endothelial cells. 
Non-endothelial dependent factors encompass aortal 
pressure, myocardial contractility output, neurohu-
moral mechanisms and myocardial metabolism17. En-
dothelial dysfunction leads to vasodilatory imbalance 
between NO and vasoconstrictor endothelin-1 and 
reduced release of anti-infl ammatory and antithrom-
botic factors17.
Since microvascular dysfunction cannot be estab-
lished by classic coronary angiography (coronarogra-
phy) and there are no other available methods at pres-
ent for visualizing vasculature smaller than 500 μm, 
other diagnostic methods are needed to indirectly 
demonstrate microvascular dysfunction. Th ese tests 
can be invasive (thermodilution and invasive evalua-
tion of coronary fl ow) or noninvasive (myocardial 
scintigraphy-radionuclide perfusion, positron emis-
sion tomography (PET), NMR)17.
Th e gold standard in the diagnosis of vascular dys-
function is invasive evaluation of coronary fl ow reserve. 
Coronary fl ow reserve is an increase in blood fl ow in 
response to metabolic or pharmacological stimuli19. 
Diminished coronary reserve is an indicator of possi-
ble ischemia, which could be provoked by increase in 
myocardial oxygen demand. Results of the above men-
tioned test indicate that microvascular dysfunction is a 
plausible cause of CSX. Novel studies using magnetic 
resonance (MR) confi rm decreased subendocardial 
perfusion in patients with CSX compared to healthy 
control group19. PET demonstrated diminished coro-
nary reserve in 50% to 60% of female patients with 
non-CAD, and MRI in 25% of the same population19. 
However, the prevalence of ischemia is probably un-
derestimated with MR considering the limited ability 
to induce stress or exertion during MR20.
Obviously, microvascular dysfunction is a very im-
portant mechanism in the development of non-CAD. 
Primary disorder in microvascular dysfunction is al-
tered (decreased) vasodilative response to adequate 
stimuli, but in a specifi c group of patients enhanced 
vasoconstrictory response can be present21.
Decreased endothelial dependent vasodilation (en-
dothelial dysfunction) is diagnosed with provocation 
tests using acetylcholine or with direct electrostimula-
tion of the right atrium, while non-endothelial depen-
dent dysfunction can be established by adenosine, 
pyridamole or papaverine provocation tests21,22. Ab-
normal vasoconstriction can be confi rmed by provoca-
tion with ergonovine, cold, hyperventilation, hand-
shake test and acetylcholine23. After performing one of 
these provocation tests, diminished coronary reserve 
should be diagnosed with one of the previously men-
tioned methods (indirectly invasive – coronary fl ow 
reserve test or noninvasive tests – PET, MR).
Based on the resu lts of our recently published re-
search24, we propose a new mechanism that could be 
added to endothelial independent mechanisms within 
the ischemic hypothesis on the development of non-
CAD. Alongside the known endothelial independent 
pathophysiological mechanisms such as aortic pres-
sure, myocardial contractility, myocardial metabolism 
and neurohumoral factors25, another possible contrib-
utor would be the type of coronary supply, specifi cally 
the left type of dominance (particularly in women), 
and absence of mixed type in men24.
Non-ischemic hypothesis
Non-ischemic hypothesis explains the CSX phe-
nomenon and non-CAD because of altered pain per-
ception25. Previous studies demonstrated that patients 
with angina and normal coronary arteries had en-
hanced pain perception to heat and electrical stimuli26. 
Th ere is evidence supporting the absence of habitua-
tion to frequent pain stimuli in these patients (habitu-
al theory)27. Furthermore, it is well known that estro-
gen has analgesic properties, which are mediated 
through opioid system, thus explaining the presence of 
chest pain in postmenopausal women with normal 
coronarography. It is possible that the lack of estrogen 
in females participates in altered chest pain percep-
tion28.
In 1988, Shapiro et al. demonstrated that intracar-
dial stimulation by infusion of saline to the right atri-
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um induced chest pain in patients with angina and 
normal coronary arteries29. It was the fi rst paper pub-
lished that explained this phenomenon using altered 
pain perception. Although results of previous studies 
indicated generally diminished tolerance to all pain 
stimuli in these patients, the study by Iannetti et al. 
denied such notion30. Earlier studies were poorly con-
trolled and badly designed, whereas new studies with 
laser pain stimuli on the skin surface established unal-
tered general pain perception. In addition, local elec-
trostimulation of the right ventricle with higher fre-
quencies demonstrated altered pain perception in the 
heart30.
Rosen et al. demonstrated that activation of the 
right frontal insula of the brain cortex in patients with 
CSX and ST changed during dobutamine stress test, 
suggesting cortical origin of this disorder31. Aff erent 
(sympathetic) and eff erent (nociceptive) fi bers can be 
aff ected as well31. Enrolment of the sympathetic heart 
system (aff erent component) can be clinically diag-
nosed by metaiodobenzylguanidine (MIBG) scintig-
raphy. In patients with CSX, radionuclide 123I- MIBG 
uptake is completely absent, although the liver and 
lung are clearly visible. Th is implicates signifi cant ab-
normality in sympathetic heart innervation in patients 
with non-CAD32. Involvement of eff erent (nocicep-
tive) fi bers is established directly with electrostimula-
tion of the right heart or pharmacologically with do-
butamine or adenosine delivered locally as intracardial 
infusion31.
Integrated ischemic and non-ischemic hypothesis
It is currently presumed that the pathophysiologi-
cal relationship between ischemic and non-ischemic 
hypothesis exists. Microvascular dysfunction and re-
peated subclinical episodes of ischemia could lead to 
structural changes in heart innervation through fi bro-
sis or prolonged mild infl ammation. Th is is presented 
as an enhanced pain perception to harmless local stim-
uli (eff erent innervation) or as a decreased uptake of 
MIBG in sympathetic heart fi bers, which implicates 
involvement of aff erent fi bers32.
Traditional risk factors such as hypertension, 
 hypercholesterolemia and diabetes have a signifi cant 
role in the development of microvascular dysfunction 
through endothelial dependent vasodilatation (endo-
thelial dysfunction) and are part of ischemic hypothe-
sis33. Insulin resistance and glucose intolerance are also 
Fig. 1. Risk factors for development of non-CAD. Th ere is a relationship between ischemic (endothelial 
and non-endothelial dependent theory) and non-ischemic (neural and habitual theory) risk factors. Repeated episodes 
of micro ischemia due to microvascular coronary dysfunction could lead to neural disorder aff ecting adrenergic 
or nociceptive fi bers through fi brosis and mild prolonged infl ammation. Habitual and neural theory could also be connected.
Z. Makarović et al. Nonobstructive coronary artery disease
532 Acta Clin Croat, Vol. 57, No. 3, 2018
associated with endothelial dysfunction34. Th e lack of 
estrogen in females and hysterectomy are part of the 
non-ischemic hypothesis based on analgesic properties 
of estrogen35, while mild infl ammation with increased 
concentration of C-reactive protein and interleukin-1 
receptor antagonists is a possible risk factor in non-
ischemic and ischemic hypothesis causing structural 
changes of neural fi bers36 (Fig. 1).
Diagnosis of Nonobstructive Coronary 
Artery Disease
Diagnosis of non-CAD is based on clinical presen-
tation and diagnostic procedures. Clinical presentation 
of angina can be more or less typical. Diagnostic tests 
in non-CAD can be invasive and noninvasive (Table 1).
and pulse pressure product during stress needed to 
cause ST changes in patients with non-CAD39.
Th erefore, patients with positive stress test are can-
didates for further invasive diagnostic work-up to con-
fi rm or exclude obstructive changes of coronary arter-
ies. Usually, direct catheterization of arteries (coronar-
ography) is performed, although there are other non-
invasive methods such as multi-slice computerized 
tomography (MSCT)6.
Some authors suggest acetylcholine or ergonovine 
test (intracoronary or intravenously) in patients with 
normal coronarography to exclude spasm of major ar-
teries. Unfortunately, this procedure is highly risky due 
to the possibility of strong vasospasm and hypoten-
sion, thus it is not part of routine clinical work-up6.
After exclusion of all non-cardiac causes, diagnosis 
of CAD is based on clinical presentation of chest pain 
and diagnostic procedures. First procedure is noninva-
sive test of physical activity (ergometry, or rarely myo-
cardial stress scintigraphy). In patients with positive 
stress test, coronarography is performed to defi nitely 
confi rm or exclude obstructive stenosis (≥50%) of epi-
cardial arteries. Spasm of major arteries can be diag-
nosed with ergonovine or acetylcholine test but due to 
the considerable risk it is not part of routine clinical 
work-up37.
Routine clinical work-up ends at this point. Addi-
tional tests for more accurate diagnosis of non-CAD 
are used only for research purposes6. In patients with 
suspected ischemic etiology (microvascular dysfunc-
tion), some pharmacological tests can be performed to 
confi rm altered vasodilatation or enhanced vasocon-
striction. Th e most commonly performed tests are ace-
tylcholine test or electrostimulation to establish endo-
thelial dependent dysfunction and adenosine, pyri-
damole or papaverine tests to establish non-endotheli-
al dependent dysfunction. Vasoconstriction can be 
diagnosed with ergonovine test or cold pressure test23. 
After implementation of one of these tests, establish-
ing induced ischemia in the microvasculature area 
(<500 μm) is necessary8.
Since small blood vessels cannot be displayed on 
coronarography, ischemia is indirectly visualized with 
invasive methods such as the test of coronary fl ow re-
serve (CFR) or with noninvasive methods such as 
myocardial scintigraphy, MR or PET19,20.
To confi rm non-ischemic origin of the disorder 
(altered pain perception), MIBG scintigraphy of sym-
Table 1. Diagnostic tests (invasive and noninvasive) 
in nonobstructive coronary artery disease (non-CAD)
Clinical presentation

• Chest pain (anginal)













•  Possible acetylcholine 
or ergonovine 
test (vasospasm)
MSCT = multi-slice computed tomography
It is very important to emphasize that non-CAD is 
diagnosed by exclusion6. Exclusion of all other non-
cardiac causes of angina such as musculoskeletal pain, 
gastrointestinal disorders, pulmonary causes and vari-
ous psychiatric disorders is necessary. In patients with 
probable angina, noninvasive diagnostic tests are per-
formed trying to confi rm ischemia through signifi cant 
ST-T changes (based on established standardized di-
agnostic criteria) mostly during exertion. Th e basic test 
of physical activity is ergometry or exercise myocardial 
perfusion scintigraphy37.
Currently, there are no defi ned criteria for diff eren-
tiating obstructive from nonobstructive disease in pa-
tients with positive stress test38. However, some au-
thors suggest several criteria such as increased pressure 
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pathetic heart innervation for visualizing aff erent dys-
function and direct heart stimulation with dobutamine 
or electrostimulator for demonstrating eff erent dys-
function can be performed25. Additional tests are also 
available such as insuffi  ciently standardized psycho-
logical tests for establishing habitual component of 
disorder, as well as absence of adaptation to repeated 
pain stimuli27. All additional diagnostic tests are sum-
marized in Table 2.
Prognosis of Nonobstructive Coronary Artery 
Disease and Prevalence of Major Cardiovascular 
Outcomes
Unlike former opinions, current studies have veri-
fi ed that patients with non-CAD have an increased 
risk of cardiac mortality11,40,41. Prognosis of non-CAD 
is not benign considering 2% risk of cardiac death or 
myocardial infarction within 30 days of disease mani-
festation11. Several studies demonstrated that advanced 
coronary atheroma could be present despite normal or 
almost normal coronary arteries42, thus increasing the 
risk of adverse acute events43. Th e Women’s Ischemia 
Syndrome Evaluation (WISE) trial, which included 
women with non-CAD, demonstrated that diff erent 
symptom profi les were associated with diff erent long-
term outcomes44. An increase in adverse cardiac events 
was observed in patients with non-CAD. Th ese fi nd-
ings suggest that normal or almost normal coronary 
arteries on coronarography do not imply benign prog-
nosis44.
Furthermore, classic defi nition of coronary disease 
symptoms encompasses retrosternal chest pain or dis-
comfort (which can irradiate into the neck, arm, jaw 
and back), with pain quality described as dull, sharp, 
crushing or burning, lasting for 2-20 minutes and 
worsened with physical activity, while alleviated with 
rest or nitroglycerin45. On the other hand, the majority 
of patients (around 70%) in the study performed by 
Johnson et al.44 presented with atypical symptoms re-
gardless of verifi ed nonobstructive or obstructive coro-
nary disease on coronarography. As a consequence of 
this symptom variability, patients with atypical presen-
tation and an increased risk of adverse cardiac events 
can be easily overlooked. Previous studies performed 
in patients with angina and normal coronarography in 
the 1960s did not demonstrate an increased prevalence 
of adverse clinical events, or increased mortality46. 
Th ose studies were performed in a small number of 
patients with short follow-up; therefore, the increased 
risk in those patients was not determined47. Th e WISE 
trial was the fi rst study that demonstrated completely 
Table 2. Additional tests for exact identifi cation of the extent of non-obstructive coronary artery disease














Increased vasoconstriction • Ergonovine
• Acetylcholine
















Noninvasive •  Myocardial scintigraphy
• MR
• PET
MIBG = 123I-methaiodobenzylguanidine; CFR = coronary fl ow reserve; MR = magnetic resonance; PET = positron emission tomography
Z. Makarović et al. Nonobstructive coronary artery disease
534 Acta Clin Croat, Vol. 57, No. 3, 2018
opposite results in females with CSX. Th ose patients 
had a three-fold higher prevalence of adverse cardio-
vascular events (including heart failure and stroke) 
compared to healthy controls during the 5-year fol-
low-up (2.4% vs. 7.9%; p=0.002)44. Th ese results were 
confi rmed by the British Columbia registry, which es-
tablished a 4 times higher probability of hospital re-
admission in females with angina and nonobstructive 
changes on coronarography presenting as acute coro-
nary syndrome compared to males during early fol-
low-up48.
However, the WISE trial was not successful in es-
tablishing statistically higher prevalence of myocardial 
infarction or cardiac death compared to healthy popu-
lation, despite numerical diff erences. Nevertheless, the 
total mortality rate was signifi cantly higher compared 
to the control group (2.1% vs. 3.0%; p=0.04)44. Th is 
observation is extremely important since a high mor-
tality rate was established for the fi rst time in women 
with non-CAD. It is considered that prognosis in fe-
males with non-CAD depends on microvascular dys-
function49. Several studies demonstrated that patients 
with CSX and established microvascular dysfunction 
had a higher probability of developing CAD in the 
future and higher prevalence of adverse cardiovascular 
events50. Moreover, investigators in the WISE trial ad-
ditionally stratifi ed patients with nonobstructive dis-
ease in two groups. First group consisted of patients 
with confi rmed ischemia using MR spectroscopy (in-
direct proof of microvascular dysfunction), whereas in 
the second group of patients diagnosis of ischemia 
with that method was not possible. In the group of 
patients with confi rmed ischemia and microvascular 
dysfunction, a higher prevalence of adverse cardiovas-
cular events was observed even when considering all 
traditional risk factors44. Th e WISE trial included only 
women, thus it is still unclear whether the same obser-
vations apply to male population.
In 2012, Jespersen et al.51. published results from 
the Copenhagen City Heart trial including 11,233 pa-
tients that underwent coronarography due to the 
symptoms of stable angina and were compared to 
healthy individuals without cardiovascular events. Sig-
nifi cantly more females (65%) compared to males 
(32%) had non-CAD among patients with stable cor-
onary disease. Th is is consistent with the observations 
from the WISE trial that 62% of patients who under-
went coronarography due to chest pain had non-CAD. 
Th e Danish trial was designed as a retrospective cohort 
study including all patients from eastern Denmark 
that underwent coronarography due to angina from 
1998 to 200951. Th is trial demonstrated that both 
males and females with anginal symptoms and normal 
or nonobstructive changes of coronary arteries had an 
increased risk of adverse cardiovascular events com-
pared to healthy population without ischemic events. 
Th at specifi c group of patients with normal coronary 
arteries or nonobstructive changes of coronary arteries 
had 52% and 85% increased risk of major adverse car-
diac events (MACE) including cardiac death, hospi-
talization due to myocardial infarction and heart fail-
ure or stroke, and 29% and 52% had an increased mor-
tality risk regardless of the cause. Th ere was no statisti-
cally signifi cant diff erence for MACE or mortality 
rate between men and women51.
Treatment of Nonobstructive Coronary 
Artery Disease
Treatment of non-CAD presents a great challenge. 
Unfortunately, therapy is often unsuccessful because 
symptoms persist at 5-year follow-up in almost 50% of 
treated women54. Th ere are few medications and pro-
cedures that are undoubtedly effi  cient in CSX treat-
ment. Experiences gathered from large clinical trials 
are lacking. Most of observations and conclusions are 
based on smaller and observational studies that in-
cluded only a few dozens of patients or less. Results of 
those trials are mostly contradictory or lacking well 
defi ned control groups for comparison. Th e Eff ects of 
Allopurinol on Coronary and Peripheral Endothelial 
Function in Patients with Cardiac Syndrome X 
(APEX) trial is one of the few clinically controlled 
pending trials (started in 2008) that is trying to evalu-
ate specifi c drug effi  cacy, in this case allopurinol, in 
treating CSX55. However, based on the current knowl-
edge, it is safe to say that beta-blockers and lifestyle 
changes modifying cardiovascular risk factors have a 
central role in non-CAD treatment55. All therapeutic 
measures in non-CAD treatment can be divided into 
medicamentous and non-medicamentous measures 
that are summarized in Table 3.
Medicamentous measures
Th ere are numerous small trials demonstrating 
 atenolol effi  cacy in CSX treatment56-58. Atenolol 
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 decreases pain, improves coronary reserve, and de-
creases ST depression during exertion test56. Th e cal-
cium channel blockers verapamil and amlodipine were 
not effi  cient compared to atenolol, although there are 
some reports indicating benefi cial eff ect of atenolol 
and amlodipine combination56. Unfortunately, con-
trolled experiences with other beta-blockers are lack-
ing. Nebivolol is the only drug investigated in patients 
with non-CAD. Nebivolol is a highly selective beta-
1-blocker with benefi cial eff ect on endothelial func-
tion, which increases bioavailability of the most potent 
endogenous vasodilator NO55. Upon intracoronary 
infusion, it increases coronary reserve in patients with 
and without obstructive changes in the epicardial ar-
teries. However, intracoronary application of this drug 
is not clinically possible, while experiences with oral 
usage are still lacking.
Investigators generally agree that beta-blockers 
have benefi cial eff ect, although there is a response vari-
ability of 19%-60%59. However, based on current re-
search, beta-blockers (especially atenolol) should be 
the fi rst line treatment in patients with CSX60.
Although expected, effi  cacy of nitrates in CSX 
treatment is still questionable. In small observational 
studies, effi  cacy was present in only 42% of patients. 
Moreover, there are some reports indicating decreased 
tolerance during the test of physical activity in those 
patients when treated with nitrates61. Th erefore, ni-
trates are recommended exclusively in combination 
with other effi  cient drugs56.
Th e xanthine derivatives aminophylline and the-
ophylline are blocking adenosine receptors, thus en-
abling more favorable redistribution of coronary fl ow 
and probably blocking adenosine eff ect in pain provo-
cation (intracoronary infusion of adenosine elicits 
chest pain in patients with CSX)6,55. Intravenous or 
oral administration of aminophylline during the test of 
physical activity increases exercise tolerance, dimin-
ishes pain perception, and decreases ST changes62,63. 
Th erefore, these medications can be recommended, 
especially in patients treated for asthma or chronic ob-
structive pulmonary disease55.
In small observational and placebo controlled tri-
als, some angiotensin-converting enzyme (ACE) in-
hibitors had certain benefi cial eff ect64, this referring to 
cilazapril65, enalapril66 and a combination of ramipril 
and statin (atorvastatin)55. Antagonists of angiotensin 
receptors (ARB), despite expectations, did not demon-
strate any favorable eff ects in a trial investigating irbe-
sartan67. For other members of this group, effi  cacy was 
neither investigated nor established.
In several studies, statins showed some effi  cacy in 
treating CSX, probably due to their anti-infl ammatory 
eff ect. Th e eff ect was present regardless of the plasma 
lipid profi le baseline values68,69. Furthermore, addition-
al synergic eff ect was established with some ACE in-
hibitors, especially for atorvastatin and ramipril6,55,68.
Of all other medications utilized in CSX treatment 
that had certain success, we should mention estrogen 
in postmenopausal women55,70, L-arginine (precursor 
Table 3. Th erapeutic recommendations for treatment of non-obstructive coronary artery disease
Th erapeutic recommendation Medicamentous treatment Non-medicamentous treatment
First line therapy Beta-blockers (atenolol) Physical training
Correction of risk factors
Rehabilitation (after myocardial infarction)








Questionable eff ect Nitrates
Calcium channel blockers
-
Eff ect not established Irbesartan (ARB)
Alpha-agonists (doxazosin, clonidine)
-
ACE = angiotensin-converting enzyme; COPB = chronic obstructive pulmonary disease; SCS = spinal cord stimulation; TENS = trans-
dermal electric nerve stimulation; EECP = extracorporeal enhanced counter pulsation; ARB = angiotensin II receptor blockers
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of vasodilator NO)71,72, metformin in patients with 
glucose intolerance73, and imipramine that is used in 
the treatment of chronic pain74,75.
Th e effi  cacy of α-antagonists (doxazosin and cloni-
dine) has not yet been established in the treatment of 
non-CAD symptoms76.
Th ere are several new drugs with probable thera-
peutic eff ect in CSX based on their mechanism of ac-
tion. However, currently there is no strong evidence to 
confi rm their effi  cacy and justify their application. 
Some of these drugs are bosentan (ET-1 inhibitor), 
cariporid (Na-H+ exchanger), fasudil (rho-kinase in-
hibitor) and trimetazidine (metabolic antianginal 
drug)55. Only nicorandil, activator of vascular potassi-
um channels with vasodilatory abilities, is eff ective in 
the treatment of microvascular coronary disease77,78.
Non-medicamentous measures
Besides the above mentioned pharmacological 
measures in the treatment of CSX symptoms, there are 
also non-medicamentous procedures that exhibited fa-
vorable eff ect in some patients. Spinal cord stimulation 
(SCS) with low voltage electric impulses aff ects pain 
modulation and diminishes pain sensation in patients 
with angina79. Th is method is approved in the treat-
ment of refractory angina in patients with CAD un-
suitable for revascularization, and has class IIb recom-
mendation according to the American College of Car-
diology/American Heart Association (AHA/ACC) 
guidelines80. Th ere are several reports indicating effi  -
cacy of this method in long-term control of symptoms 
in patients with CSX79,81.
Similar procedure is transdermal electric nerve 
stimulation (TENS). Th is procedure improves coro-
nary fl ow without altering microvasculature diameter 
and has benefi cial eff ect in eliminating symptoms82-84.
Extracorporeal enhanced counter pulsation 
(EECP) consists of periodical infl ating and defl ating 
pressure cuff s on lower extremities that proved effi  -
cient in recovering endothelial function and in some 
small studies led to diminishing anginal symptoms85.
Lifestyle modifi cations and aff ecting cardiovascu-
lar risk factors are basic recommendations for patients 
with non-CAD55. Physical exercise improves coronary 
reserve and exercise tolerance, and diminishes symp-
toms in both CAD and non-CAD86. Additional im-
provement of exercise tolerance, quality of life, and 
benefi cial eff ect on anginal symptoms can be achieved 
through rehabilitation87,88. Recommendations are 
weight reduction89, smoking cessation90 and low fat or 
Mediterranean diet91, which improves endothelial dys-
function55.
New Classifi cation of Nonobstructive Coronary 
Artery Disease Suggested
We propose here a new classifi cation of non-CAD, 
separating the whole syndrome in type I (ischemic dis-
ease) and type II (non-ischemic disease), based on 
which clinical syndrome predominates. Each of these is 
further divided based on the existing mechanism and is 
marked by letters A, B or C, as shown in Table 4.
Disorder 1A represents endothelial dependent re-
duced vasodilatation, which clinically corresponds to 
Table 4. Suggested classifi cation of pathophysiological mechanisms in nonobstructive coronary artery disease 
(non-CAD)
Type of non-CAD disorder Underlying mechanism Clinical presentation
Type I Ischemic 
mechanisms
1A Endothelium dependent 
reduced vasodilation
Endothelial dysfunctio n






• Type of coronary artery supply
1C Vasoconstriction Vasospasm
Type II Non-ischemic 
mechanisms
2A Neurogenic aff erent Adrenergic disorder
2B Neurogenic eff erent Nociceptive disorder
2C Habitual Behavioral disorder
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endothelial dysfunction. Established cardiovascular 
risk factors such as smoking, dyslipidemia, diabetes 
mellitus or hypertension are involved in the patho-
physiology of this mechanism, as well as NO, enothe-
lin-1, and other anti-infl ammatory and antithrombot-
ic factors. Disorder 1B represents endothelial indepen-
dent mechanisms. Clinically, this includes aortic pres-
sure, myocardial contractility, myocardial metabolism, 
neurohumoral factors, and type of coronary artery sup-
ply. As previously highlighted, left dominance in 
women is more frequent in non-CAD, as well as the 
absence of mixed dominance in men. Disorder 1C 
represents increased vasoconstriction. Th is mechanism 
contains both microvascular and macrovascular (vaso-
spastic) vasoconstriction, but without permanent ob-
struction of coronary arteries >50%. In a broader sense, 
this refers to the bridging of coronary arteries as well, 
which represents dynamic stenosis in the location 
where major coronary artery is running intramyocar-
dially. Th is is mostly seen in the left anterior descend-
ing artery, but may be seen in other coronary arteries as 
well.
Non-ischemic mechanisms may also be divided into 
three basic groups, and are marked by letters A, B and 
C: 2A is a neurogenic aff erent mechanism, which clini-
cally represents adrenergic disorder of heart innerva-
tion; 2B is neurogenic eff erent mechanism that clini-
cally represents nociceptive disorder; and 2C is habitual 
mechanism that represents behavioral disorder.
In clinical practice, the same patient may have 
more of less combined induced mechanisms. However, 
there is always one predominant mechanism in clinical 
presentation of non-CAD, and the disorder can be 
classifi ed by that predominant mechanism.
Certainly, microvascular dysfunction plays a sig-
nifi cant role in the development of non-CAD, but 
other mechanisms should not remain unattended. 
Th ese pathophysiological mechanisms are well defi ned 
and lead to anginal symptoms, and aff ect major coro-
nary arteries, not the microvasculature. Th is especially 
refers to vasospastic, Prinzmetal’s angina, and phe-
nomenon of myocardial bridging. Both aff ect major 
coronary arteries and should be placed among the 
mechanisms of non-CAD.
With this new classifi cation, the aim is to include 
all the known pathophysiological mechanisms and 
align classifi cation to current diagnostic testing, thus 
hopefully contributing to better understanding, timely 
diagnosis and comprehensive management of non-
CAD.
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Sažetak
NEOPSTRUKTIVNA KORONARNA BOLEST – KLINIČKA VAŽNOST, DIJAGNOSTIKA, 
LIJEČENJE I PRIJEDLOG NOVE PATOFIZIOLOŠKE KLASIFIKACIJE
Z. Makarović, S. Makarović, I. Bilić-Ćurčić, I. Mihaljević i D. Mlinarević
Novi podaci prikupljeni iz velikih kliničkih ispitivanja pokazuju da je neopstruktivna koronarna bolest (ne-OKB) kli nički 
entitet koji se ne smije zanemariti. Procjenjuje se da se u 50% ženske populacije koja se podvrgava koronarografi ji dijagno-
sticira ne-OKB. Također postoji povećanje učestalosti ne-OKB u oba spola, što je vjerojatno posljedica postupnog širenja 
kliničkih indikacija za koronarografi ju u bolesnika s anginom pektoris. Nadalje, s obzirom na povećani rizik od smrtnosti koji 
je nedavno ustanovljen, prognoza ne-OKB nije dobroćudna kao što se ranije mislilo. Međutim, koncept i defi nicija ne-OKB 
ostaju nedovoljno defi nirani, što uzrokuje poteškoće kako u dijagnozi tako i u liječenju. Jedan od glavnih nedostataka je 
 dijagnostika ne-OKB koja se temelji na dijagnozi isključivanja. Nadalje, liječenje ne-OKB i dalje predstavlja velik izazov, a 
optimalnu terapiju tek treba odrediti. Postoje dvije glavne hipoteze koje objašnjavaju patofi ziološke mehanizme ne-OKB. 
Ishemijska hipoteza temelji se na mikrovaskularnoj disfunkciji, a neishemijska hipoteza na promijenjenoj percepciji boli. 
Ovaj pregledni članak obuhvaća širok spektar patofi zioloških mehanizama ne-OKB i predlaže novi način klasifi kacije teme-
ljen na glavnom poremećaju koji je uključen u patofi ziologiju: tip I. (ishemijski mehanizam) i tip II. (ne-ishemijski mehani-
zam), ovisno o tome koji mehanizam prevladava. Nadamo se da će to omogućiti nove spoznaje u razumijevanju ovoga pore-
mećaja, što dovodi do točne i rane dijagnoze i uspješnog liječenja, osobito s obzirom na povećani rizik smrtnosti kod ovih 
bolesnika.
Ključne riječi: Koronarne arterije, bolesti; Klasifi kacija; Dijagnostika; Angiografi ja
